Hyperion Therapeutics Completes Follow-On Offering and Announces Exercise of Underwriters' Over-Allotment Option

Hyperion Therapeutics Completes Follow-On Offering and Announces Exercise of
Underwriters' Over-Allotment Option

SOUTH SAN FRANCISCO, Calif., March 13, 2013 (GLOBE NEWSWIRE) -- Hyperion
Therapeutics, Inc. (Nasdaq:HPTX) announced today the completion of its
follow-on offering of 2,875,000 shares of common stock. In addition, the
underwriters exercised their over-allotment option in full and purchased an
additional 431,250 shares of common stock. All such shares were sold by
Hyperion at the follow-on offering price of $20.75 per share. The net proceeds
to Hyperion from this offering are approximately $64.5 million, after
deducting underwriter discounts and commissions. Leerink Swann LLC and Cowen
and Company, LLC acted as joint book-running managers for the offering, and
Needham & Company, LLC and JMP Securities LLC acted as co-managers for the
offering.

A registration statement relating to these securities was declared effective
by the Securities and Exchange Commission on March 7, 2013. This offering is
being made only by means of a prospectus, copies of which may be obtained from
Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th
Floor, Boston, MA 02110, by calling (800) 808-7525, ext. 4814, and Cowen and
Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, Attn: Prospectus Department, by calling (631) 274-2806, or
faxing (631) 254-7140.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or other jurisdiction.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company
committed to developing and delivering life-changing treatments for orphan
diseases and hepatology.

CONTACT: Shari Annes, Investor Relations
         (650) 888-0902
         sannes@annesassociates.com
        
         Kristie Kuhl, Media Relations
         (203) 556-7417
         kkuhl@makovsky.com
 
Press spacebar to pause and continue. Press esc to stop.